plantar fasciitis. Plantar fascial fibromatosis
Conditions
Interventions
Intervention 1: Intervention group: included 30 patients who are treated with 150 unit botulinum toxin injection (Masport, Masson Darou) at the origin of the plantar fascia with 1 cc of 2% lidocaine.
Sponsors
Shahid Beheshti University of Medical Sciences
Eligibility
Sex/Gender
All
Age
30 Years to 60 Years
Inclusion criteria
Inclusion criteria: People aged 30 to 60 years who have been diagnosed with unilateral plantaris fasciitis based on history and clinical examination. After 3 months from the onset of symptoms and the use of conservative treatments, including rest, anti-inflammatory drugs, physical modalities and exercise therapy, the patient's symptoms have not improved.
Exclusion criteria
Exclusion criteria: History of previous surgery for plantaris fasciitis. History of injection for treatment of plantaris fasciitis in the last 3 months. Bilateral plantaris fasciitis Presence of systemic inflammatory diseases such as rheumatoid arthritis and seronegative arthritis. History of vascular insufficiency and neuropathic heel pain Existence of concomitant diseases in the lower limbs, such as a history of tarsal tunnel syndrome symptoms and positive tinel sign. Presence of effusion in the ankle, which suggests an intra-articular disease Old fracture of calcaneal bone. Presence of retrocalcaneal bursitis, Achilles tendinopathy and ankle osteoarthritis Any ankle or foot deformity, including flat foot and pes cavus. Uncontrolled diabetes BMI more than 33 Radicular low back pain Presence of local infection or trauma near the injection site Use of anticoagulants Presence of diseases that involve the neuromuscular junction, such as myasthenia gravis and Eaton Lambert Known allergy and sensitivity to botulinum toxin or corticosteroids Presence of cyst or bone mass in the area of ??the heel Pregnancy or breastfeeding
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Evaluation of the patient's heel pain. Timepoint: At the beginning of the study (before intervention) and 6 weeks and 24 weeks after the intervention. Method of measurement: Visual analogue scale (VAS).;Assessment of plantar fascia thickness. Timepoint: At the beginning of the study (before intervention) and 6 weeks and 24 weeks after the intervention. Method of measurement: Measuring the thickness of the plantar fascia with ultrasonography.;Pain pressure threshold. Timepoint: At the beginning of the study (before intervention) and 6 weeks and 24 weeks after the intervention. Method of measurement: Algometer.;Assessment of the patient's performance in daily tasks. Timepoint: At the beginning of the study (before intervention) and 6 weeks and 24 weeks after the intervention. Method of measurement: Using the FFI-R questionnaire. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactAli Nazari Nodoushan
Shahid Beheshti University of Medical Sciences
Outcome results
None listed